Preclinical data presented at the American Association for Cancer Research annual meeting provide further support for the potential of SRK-181 to overcome primary resistance to checkpoint blockade therapy (CBT) TGFβ1-specific inhibition by SRK-181-mIgG1 was sufficient to render both TGFβ1-expressing and TGFβ1/TGFβ3 co-expressing mouse tumor models sensitive to anti-PD1 immunotherapy, suggesting TGFβ1 is the key isoform contributing to CBT resistance Combination…
Read More